P1047 (10163): Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] L1 Virus-Like Particle [VLP] Vaccine (Gardasil®) in HIV-Infected Children > 7 to < 12 Years of Age

Study Status Study Restriction


Not Applicable

Sites where the study was implemented:

CRS ID Site Name City Country


Boston Medical Center Pediatric HIV Program


United States of America


Rush University Cook County Hospital Chicago NICHD CRS


United States of America

Study contacts:

CTS: IMPAACT Operations Center


Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.